India is likely to have a vaccine against the coronavirus disease (Covid-19) early next year and it will possibly come from various sources, Union health minister Harsh Vardhan said at a meeting of the Group of Ministers on Tuesday. , according to the news agency. AND ME.
“We hope that early next year we will have vaccines in the country from perhaps more than one source. Our groups of experts are formulating strategies to plan how to implement the distribution of the vaccine in the country ”, said the Minister of Health, quoted by ANI.
Follow live updates on coronavirus here
World Health Organization (WHO) chief scientist Soumya Swaminathan has also said that a vaccine will be ready for registration in late 2020 or early next year at the earliest.
“As you know, we now have about 40 candidate vaccines at some stage of clinical trials, and 10 of them are in phase three, which are late-stage clinical trials, which will inform us about efficacy and safety,” she He said.
Vardhan had previously said that the government is working collaboratively with state governments to collect data to ensure fair and equitable distribution of vaccines once they are ready. “Our top priority is how to guarantee a vaccine for each and everyone in the country,” he had said.
Click here full coverage of coronavirus
In the latest episode of the weekly Sunday Samwad, the Minister of Health informed the public about the key factors that will be taken into account to know the priority groups. “The prioritization of groups to be vaccinated will be based on key considerations, first is the occupational risk to the risk of exposure to infection and second is the risk of developing severe disease and increased mortality,” he said.
On the number of vaccines that will be available, the Health Minister said on Sunday that given the size of the country’s population, India may have to work with more than one vaccine manufacturer to ensure that everyone can access the injection. “All Covid-19 vaccines currently in India are in phase 1, 2 or 3 trials with expected results. Adequate safety and efficacy data are required for approval of the emergency use authorization vaccine to ensure patient safety. The further course of action will be based on the data generated, ”he added.
.
